FDA recall record

Nystatin Oral Suspension, USP 100,000 units per mL Cherry/Peppermint Flavor, 16 fl oz recall — FDA D-0824-2020

Subpotent: Out of specification for assay at the 12-month time point.

Class IIclassification
D-0824-2020official record ID
Feb 5, 2020report date

Recall record at a glance

Official recordD-0824-2020
CategoryDrug Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmPharmaceutical Associates Inc.
Report dateFeb 5, 2020
Recall initiation dateJan 14, 2020
Quantity6288 16 oz bottles
LocationGreenville, SC, United States

Official product description

Nystatin Oral Suspension, USP 100,000 units per mL Cherry/Peppermint Flavor, 16 fl oz (473 mL) Rx Only, pai, Pharmaceutical Associates, Inc. Greenville, SC 29605. NDC 0121-0810-16

Why the product was recalled

Subpotent: Out of specification for assay at the 12-month time point.

Distribution information

Distributed Nationwide in the US

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.